Global Medical Cannabis Leader Khiron Opens New Zerenia™ Clinic and Retail Pharmacy in Colombia


Ryan Allway

April 11th, 2022

News, Top News


Continues market leadership in ColombiaLatin America’s only country with universal health coverage for medical cannabis

 

  • Market leader in the Colombian medical cannabis market, with Q1 2022 volume sales exceeding 21,400 units, up 280% YoY and more than 40% of all 2021
  • New clinic continues Khiron’s unique patient acquisition and retention strategy, adding more than 20% of patient capacity to existing network
  • Located in El Ensueño shopping mall in Bogota, adjacent to various insurer´s referral centers. In Q1 2022, more than 85% of all patients receiving Khiron´s medical cannabis products in Colombia were covered by insurance programs
  • Opens its first retail pharmacy, fully licensed to dispense High and Low THC medical cannabis products to patients outside the Company´s own clinic network

 

TORONTOApril 11, 2022 /CNW/ – Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV:KHRN)(OTCQX:KHRNF)(Frankfurt:A2JMZC), a global medical cannabis leader with core operations in Latin America and Europe, is pleased to announce the opening of a new Zerenia™ clinic location and a new retail pharmacy in Colombia.

 

Following the announcement at the beginning of the year by the Government of Colombia on mandatory insurance coverage for medical cannabis products, Khiron opens a new clinic location in the city of Bogota, with a maximum annual capacity of 40,000 consults per year. The new clinic, located in El Ensueño shopping mall in Bogota´s fastest growing districts with more than 850,000 people, will allow the Company to continue is market leadership in Colombia and offer more services to existing and current patients.

 

In addition, the Company has opened its first retail pharmacy location within this shopping center. This pharmacy will allow the Company to sell medical cannabis products to patients outside its own ZereniaTM network and dispense High and Low THC medical cannabis to insurance companies in the country.

 

Alvaro Torres, Khiron CEO and Director comments, “Khiron has become a clear leader in the Colombian medical cannabis market because of its unique go-to-market strategy, anchored in our ZereniaTM clinic model. This new expansion within Bogota capitalizes on the Colombian government’s decision on mandatory insurance coverage, and we aim to get closer to our patients and insurers, to improve quality of life. With our new retail pharmacy, we aim to be able to offer more access to patients outside our clinic network and to provide a dispensing alternative to insurers, thereby increasing our market leadership within Colombia. As we continue to grow, our leadership is expanding to Latin America and Europe, thanks to our ability to generate evidence, offer high quality products, and create an excellent patient-focused healthcare service that improves quality of life”.

 

About Khiron Life Sciences Corp.

Khiron is a leading integrated international medical cannabis company with core operations in Latin America and Europe. Leveraging medical health clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific expertise, and high-quality product portfolio, to drive prescriptions and brand loyalty with patients worldwide. The Company has a sales presence in ColombiaPeruGermany, UK, and Brazil and is positioned to commence sales in Mexico. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and diverse executive team and Board of Directors.

 

Visit Khiron online at investors.khiron.ca

Linkedin https://www.linkedin.com/company/khiron-life-sciences-corp/

Cautionary Notes

 

Forward-Looking Statements

This press release may contain certain “forward-looking information” and “forward-looking statements” within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron’s control, including the risk factors discussed in Khiron’s Annual Information Form which is available on Khiron’s SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and is made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

 

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

 

Global Medical Cannabis Leader Khiron Opens New ZereniaTM Clinic and Retail Pharmacy in Colombia (CNW Group/Khiron Life Sciences Corp.)
Global Medical Cannabis Leader Khiron Opens New ZereniaTM Clinic and Retail Pharmacy in Colombia (CNW Group/Khiron Life Sciences Corp.)
Global Medical Cannabis Leader Khiron Opens New ZereniaTM Clinic and Retail Pharmacy in Colombia (CNW Group/Khiron Life Sciences Corp.)
Global Medical Cannabis Leader Khiron Opens New ZereniaTM Clinic and Retail Pharmacy in Colombia (CNW Group/Khiron Life Sciences Corp.)
Khiron Life Sciences Corp (CNW Group/Khiron Life Sciences Corp.)
Khiron Life Sciences Corp (CNW Group/Khiron Life Sciences Corp.)

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading